Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer

According to the 6th edition of the Japanese Gastric Cancer Treatment Guidelines; total gastrectomy with D2 lymphadenectomy includes groups No.1 to No.7, No.8a, No.9, No.11p, No.11d, and No.12a. The No.4sa group lymph nodes are defined as the lymph nodes along the short gastric vessel, No.10 group lymph nodes are defined as the lymph nodes at the splenic hilum including the lymph nodes at the roots of the short gastric arteries. In routine total gastrectomy with D2 combined with CME surgery, the standard practice involves resection of the short gastric mesentery (No.4sa group and No. 10 group). There are typically 3-4 short gastric arteries in the human body, further investigation is required to determine the lymph node metastasis rates in each short gastric mesentery. Patients undergoing total gastrectomy with D2 combined with CME will have their short gastric mesenteries anatomically separated for examination, and this aims to analyze the positive rate of lymph nodes in the short gastric mesentery and investigate the correlation between tumor location, staging, and lymph node metastasis in the short gastric mesentery.

Inclusion criteria

• Aged older than 18 years and younger than 85 years
• Primary gastric adenocarcinoma confirmed by preoperative pathology result
• cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
• Patients who received total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
• American Society of Anesthesiologists (ASA) class I, II, or III
• Written informed consent

Exclusion criteria

• Negative preoperative biopsy
• Too late tumour stage or metastasis (cT4b/M1)
• BMI>30 kg/m2
• previous neoadjuvant chemotherapy or radiotherapy
• Previous upper abdominal surgery
• Combined with other malignant diseases
• Reject operation